In a synthetic lethal interaction, the targeted therapy of BRCA1/2-mutant ovarian cancer has been achieved using PARP inhibitors [14], since these tumors are deficient for the repair of dsDNA breaks by HR repair pathways [15]. This evidence concerns the gene BRCA1 and ovarian cancer.